Not applicableUnknownNCT01034891What this trial is testingWomen At Risk: The High Risk Breast Cancer ProgramWho this might be right forBreast Cancer New York Presbyterian Hospital 2,000
Testing effectiveness (Phase 2)UnknownNCT05834582What this trial is testingNeoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast CancerWho this might be right forTNBC - Triple-Negative Breast Cancer The First Affiliated Hospital with Nanjing Medical University 60
Not applicableStudy completedNCT03470402What this trial is testingDecision Support for BRCA Testing in Ethnically Diverse WomenWho this might be right forBreast CancerBRCA1 MutationBRCA2 Mutation+1 more Columbia University 276
Early research (Phase 1)Study completedNCT04672460What this trial is testingA Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid TumorsWho this might be right forAdvanced Solid TumorsSolid TumorsOvarian Cancer+5 more Pfizer 73
Testing effectiveness (Phase 2)Looking for participantsNCT06395519What this trial is testingPARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesWho this might be right forAdvanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+10 more 858 Therapeutics, Inc. 120
Not applicableStudy completedNCT03066856What this trial is testingDietary Intervention and BRCA PenetranceWho this might be right forDietary ModificationBRCA1 MutationBRCA2 Mutation+1 more Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 502
Testing effectiveness (Phase 2)Active Not RecruitingNCT04584255What this trial is testingNiraparib + Dostarlimab In BRCA Mutated Breast CancerWho this might be right forStage I Breast CancerStage II Breast CancerStage III Breast Cancer+5 more Dana-Farber Cancer Institute 62
Testing effectiveness (Phase 2)Study completedNCT01506609What this trial is testingStudy Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer AbbVie 294
Not applicableLooking for participantsNCT06792721What this trial is testingMEASUREMENT OF CIRCULATING MUTATION BURDENWho this might be right forBreast CarcinomaGenetic Predisposition to CancerBRCA Mutation+2 more Centre Francois Baclesse 30
Not applicableLooking for participantsNCT03667417What this trial is testingGenetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene MutationWho this might be right forBreast CancersOvarian Cancers Institut Paoli-Calmettes 5,000
Not applicableUnknownNCT04368442What this trial is testingCohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic MutationWho this might be right forBreast Cancer Metastatic Samsung Medical Center 583
Early research (Phase 1)Study completedNCT05904730What this trial is testingPhase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 MutationsWho this might be right forBreast CancerOvarian CancerBreast Neoplasms+5 more Lynkcell Europe 10
Large-scale testing (Phase 3)Active Not RecruitingNCT04915755What this trial is testingEfficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular DiseaseWho this might be right forNeoplasms, Breast GlaxoSmithKline 40
Early research (Phase 1)Not Yet RecruitingNCT06614751What this trial is testingA PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR PathwayWho this might be right forSolid CancersBRCA MutationHRD Cancer+8 more Danatlas Pharmaceuticals Co., Ltd 112
Not applicableLooking for participantsNCT07292246What this trial is testingA Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)Who this might be right forBreast CancerBRCA 1 Gene MutationBRCA 2 Gene Mutation+5 more Vasileios Kalles 15
Large-scale testing (Phase 3)UnknownNCT04296370What this trial is testingFluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA MutationWho this might be right forTreatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation Jiangsu HengRui Medicine Co., Ltd. 474
Early research (Phase 1)UnknownNCT02225015What this trial is testingCancer Prevention in Women With a BRCA MutationWho this might be right forBRCA1 Gene MutationBRCA2 Gene MutationBreast Cancer+1 more Women's College Hospital 300
Not applicableActive Not RecruitingNCT04009148What this trial is testingCascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer SyndromeWho this might be right forBRCA-Mutated Ovarian CarcinomaBRIP1 Gene MutationMSH2 A636P+5 more NYU Langone Health 118
Early research (Phase 1)Study completedNCT05258747What this trial is testingA Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast CancerWho this might be right forOvarian CancerBreast Cancer Sandoz 70
Not applicableStudy completedNCT02122588What this trial is testingOVArian Cancer Non-Interventional Study - OVATARWho this might be right forOvarian, Peritoneal, Fallopian Tube Cancer, BRCAm+ in Russia AstraZeneca 503